StockNews.com Initiates Coverage on Corvus Pharmaceuticals (NASDAQ:CRVS)

Equities researchers at StockNews.com assumed coverage on shares of Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the stock.

Separately, LADENBURG THALM/SH SH initiated coverage on shares of Corvus Pharmaceuticals in a research note on Friday, October 7th. They issued a “buy” rating and a $2.00 price objective on the stock.

Corvus Pharmaceuticals Stock Up 2.8 %

NASDAQ:CRVS opened at $0.87 on Friday. Corvus Pharmaceuticals has a 12 month low of $0.70 and a 12 month high of $2.17. The firm has a market cap of $40.68 million, a price-to-earnings ratio of -0.99 and a beta of 0.98. The company’s 50 day moving average is $0.89 and its 200-day moving average is $0.91.

Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) last released its quarterly earnings results on Thursday, November 3rd. The company reported ($0.32) EPS for the quarter. Research analysts predict that Corvus Pharmaceuticals will post -0.92 EPS for the current fiscal year.

Insider Transactions at Corvus Pharmaceuticals

In related news, CEO Richard A. Md Miller acquired 50,000 shares of the stock in a transaction dated Tuesday, December 13th. The shares were acquired at an average price of $0.74 per share, for a total transaction of $37,000.00. Following the completion of the purchase, the chief executive officer now owns 1,480,119 shares in the company, valued at approximately $1,095,288.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have purchased 100,000 shares of company stock worth $75,000. Insiders own 29.70% of the company’s stock.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Bailard Inc. acquired a new stake in Corvus Pharmaceuticals during the third quarter worth $33,000. State Street Corp boosted its stake in Corvus Pharmaceuticals by 12.2% during the first quarter. State Street Corp now owns 112,603 shares of the company’s stock worth $185,000 after buying an additional 12,203 shares in the last quarter. Acadian Asset Management LLC boosted its stake in Corvus Pharmaceuticals by 72.6% during the first quarter. Acadian Asset Management LLC now owns 140,118 shares of the company’s stock worth $228,000 after buying an additional 58,952 shares in the last quarter. Two Sigma Investments LP boosted its stake in Corvus Pharmaceuticals by 19.0% during the third quarter. Two Sigma Investments LP now owns 429,708 shares of the company’s stock worth $352,000 after buying an additional 68,674 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its stake in Corvus Pharmaceuticals by 28.6% during the third quarter. Two Sigma Advisers LP now owns 480,100 shares of the company’s stock worth $393,000 after buying an additional 106,700 shares in the last quarter. Institutional investors and hedge funds own 47.45% of the company’s stock.

Corvus Pharmaceuticals Company Profile

(Get Rating)

Corvus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor.

Read More

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.